Interview with Hiro Fukutomi, Managing Director, Takeda UK
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Address: Richmond House, 79 Whitehall, London SW1A 2NS,United Kingdom
Tel: +44 (0)20 7210 4850
Web: http://www.dh.gov.uk/health/about-us/
The Department of Health’s purpose is to improve England’s health and well-being and in doing so achieve better health, better care, and better value for all.
The vision for health and social care is focused around five key priorities:
A patient-led NHS
Delivering better health outcomes
A more autonomous and accountable system
Improved public health
Reforming long-term and social care
The work of the Department of Health centres around three strategic objectives.
• Better health and well-being for all: helping people stay healthy and well; empowering people to live independently; and tackling health inequalities.
• Better care for all: the best possible health and social care that offers safe and effective care, when and where people need it; and empowering people in their choices.
• Better value for all: delivering affordable, efficient and sustainable services; contributing to the wider economy and the nation.
What is the importance of the UK operations for Takeda worldwide? Our UK operation was established in 1997 and is relatively younger than other affiliates in Europe such as Takeda…
Before joining Norgine in May 2004, you were active in larger pharmaceutical companies. What made you decide to join a smaller player? There were a few reasons. The first factor…
You used to be the Managing Director of Ranbaxy in China. Having moved to a directorship in the UK, what professional challenges do you see in this country that distinguish…
Today, Alliance Pharma Plc. represents a true pharmaceutical success story in the UK, distributing to 24 countries and moving towards GBP 50m annual turnover in just twelve years. If we…
Before joining Bristol-Myers Squibb (BMS), you have spent roughly twenty years with GSK. Can you describe the trajectory of your career and explain what attracted you in BMS? Before joining…
Thank you for having us today to give our readers an overview of the capabilities and contribution of NICE in the UK. Dr Richard Barker of ABPI has already pointed…
Astellas’s European headquarters is based in the UK. What does the UK market represent for the company? Speaking from a global perspective, 60% of Astellas’ business is based in Japan…
This year’s Q1 results for Novo Nordisk were extremely positive with a 23% increase in profit. While this growth was mostly driven by the US and emerging markets, what does…
The UK is leading the biotech turn, and is recognized as the largest biotech market in Europe. Why did Almirall only decide to enter this market until late 2007? Almirall…
You were previously managing the Merck/Schering-Plough joint venture in the US, and arrived in the UK 2 years ago. What did you set out for yourself as head of the…
It are exciting times for the UK, with the public healthcare system undergoing so many changes. The Office of Life Sciences (OLS) and the Therapeutic Capability Clusters are just some…
As part of a panel discussion with Claudia Hammond of the BBC last year, you commented on the fairly poor relationship between the NHS and industry, and the need to…
See our Cookie Privacy Policy Here
